Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajem1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * *   Welcome to STN International   * * * * * * * * *

 NEWS 1   Web Page for STN Seminar Schedule - N. America
 NEWS 2 JAN 02   STN pricing information for 2008 now available
 NEWS 3 JAN 16   CAS patent coverage enhanced to include exemplified
                    prophetic substances
 NEWS 4 JAN 28   USPATFULL, USPAT2, and USPATOLD enhanced with new
                    custom IPC display formats
 NEWS 5 JAN 28   MARPAT searching enhanced
 NEWS 6 JAN 28   USGENE now provides USPTO sequence data within 3 days
                    of publication
 NEWS 7 JAN 28   TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 8 JAN 28   MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 9 FEB 08   STN Express, Version 8.3, now available
 NEWS 10 FEB 20   PCI now available as a replacement to DPCI
 NEWS 11 FEB 25   IFIREF reloaded with enhancements
 NEWS 12 FEB 25   IMSPRODUCT reloaded with enhancements
 NEWS 13 FEB 29   WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                    U.S. National Patent Classification
 NEWS 14 MAR 31   IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                    IPC display formats
 NEWS 15 MAR 31   CAS REGISTRY enhanced with additional experimental
                    spectra
 NEWS 16 MAR 31   CA/CAplus and CASREACT patent number format for U.S.
                    applications updated
 NEWS 17 MAR 31   LPCI now available as a replacement to LDPCI
 NEWS 18 MAR 31   EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19 APR 04   STN AnaVist, Version 1, to be discontinued
 NEWS 20 APR 15   WPIDS, WPINDEX, and WPIX enhanced with new
                    predefined hit display formats
 NEWS 21 APR 28   EMBASE Controlled Term thesaurus enhanced
 NEWS 22 APR 28   IMSRESEARCH reloaded with enhancements
 NEWS 23 MAY 30   INPAFAMDB now available on STN for patent family
                    searching
 NEWS 24 MAY 30   DGENE, PCTGEN, and USGENE enhanced with new homology
                    sequence search option
 NEWS 25 JUN 06   EPFULL enhanced with 260,000 English abstracts
 NEWS 26 JUN 06   KOREAPAT updated with 41,000 documents
 NEWS 27 JUN 13   USPATFULL and USPAT2 updated with 11-character
                    patent numbers for U.S. applications
 NEWS 28 JUN 19   CAS REGISTRY includes selected substances from
                    web-based collections
 NEWS 29 JUN 25   CA/CAplus and USPAT databases updated with IPC

                        reclassification data
 NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
                        patent records
 NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
                        options to display authors and affiliated
                        organizations
 NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist
                        Assistant and BLAST plug-in
 NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
                 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS   STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN   Welcome Banner and News Items
 NEWS IPC8   For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:06:52 ON 14 JUL 2008

=> FIL REGISTRY
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                    ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 13:07:04 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1
DICTIONARY FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-533,555-1.str

chain nodes :
10 11 13 14
ring nodes :
1   2   3   4   5   6   7   8   9   12 15 16 17 18 19 20 21 22 23 24
chain bonds :
7-10 8-11 10-12 10-13 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-21 12-24 15-16 15-20 16-17
  17-18 18-19 19-20 21-22 22-23 23-24
exact/norm bonds :
5-7 6-9 7-8 7-10 8-9 8-11 10-13 12-21 12-24 14-15 15-16 15-20 16-17
17-18 18-19 19-20 21-22 22-23 23-24
exact bonds :
10-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:07:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   10 TO ITERATE

100.0% PROCESSED   10 ITERATIONS   5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE   **COMPLETE**
                         BATCH   **COMPLETE**
PROJECTED ITERATIONS: 11 TO   389
PROJECTED ANSWERS: 5 TO   234

L2   5 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:07:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   170 TO ITERATE

100.0% PROCESSED   170 ITERATIONS   107 ANSWERS
SEARCH TIME: 00.00.01

L3   107 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                ENTRY   SESSION
FULL ESTIMATED COST   178.36   178.57

FILE 'CAPLUS' ENTERED AT 13:07:48 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 14 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 13 Jul 2008 (20080713/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4   2 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L4   ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:33844 CAPLUS
DOCUMENT NUMBER: 146:119982
TITLE: A subtype of non-small cell lung carcinoma (NSCLC)
                           tumors dependent on platelet-derived growth factor
                           receptor α and its diagnosis and treatment
INVENTOR(S):   Rikova, Klarisa; Polakiewicz, Roberto; Guo, Ailan;
                           Crosby, Katherine; Zeng, Qingfu; Lee, Kimberly
PATENT ASSIGNEE(S):   Cell Signaling Technology, Inc., USA
SOURCE: PCT Int. Appl., 98pp.
                           CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

        PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
        ---------------   ----   --------   --------------------   --------
        WO 2007005027   A1   20070111   WO 2005-US23858   20050705
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
            SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
            ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
        US 20070148711   A1   20070628   US 2005-174051   20050705
        AU 2005334101   A1   20070111   AU 2005-334101   20050705
        CA 2617201   A1   20070111   CA 2005-2617201   20050705
        EP 1907842   A1   20080409   EP 2005-768977   20050705
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
        KR 2008030648   A   20080404   KR 2008-702716   20080131
PRIORITY APPLN. INFO.:   US 2005-174051   A 20050701

                                              WO 2005-US23858   W 20050705

AB   A previously unidentified subset of mammalian non-small cell lung
      carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha
      drives the disease is identified. The receptor can be used as a marker
to
      identify these tumors and as a target for cancer chemotherapy using
      PDGFRα-inhibiting drugs. The invention also provides methods for
      inhibiting the progression of a mammalian NSCLC tumor in which
      PDGFRα is expressed, and for determining whether a compound inhibits the
      progression of a PDGFRα-expressing mammalian NSCLC tumor.
      PDGFRα was identified as extensively phosphorylated in NSCLC cell
      lines. Immunoassays showed that the receptor was present in H1703 cells,
      but not in A549 cells. H1703 cells were sensitive to inhibition the
      protein tyrosine kinase inhibitor Gleevec. A survey of patients showed

L4   ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN   (Continued)
      that PDGFRα was present in 6% of NSCLC cases.
IT   918312-08-0
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
          (for inhibition of growth of PDGFRα-dependent NSCLC; subtype of
          NSCLC tumors dependent on PDGFRα and its diagnosis and treatment)
RN   918312-08-0 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)(5-
      methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)

REFERENCE COUNT: 3   THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                  RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4   ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:493723 CAPLUS
DOCUMENT NUMBER: 141:54195
TITLE: Preparation of oxindole derivatives as kinase
                           modulators
INVENTOR(S):   Bannen, Lynne Canne; Brown, S. David; Cheng, Wei; Co,
                           Erick Wang; Nuss, John M.; Kim, Moon Hwan; Klein,
                           Rhett Ronald; Le, Donna T.; Lew, Amy; Mac, Morrison
                           B.; Parks, Jason Jevious; Wen, Zhaoyang; Xu, Wei
PATENT ASSIGNEE(S):   Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 120 pp.
                           CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

        PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
        ---------------   ----   --------   --------------------   --------
        WO 2004050681   A2   20040617   WO 2003-US36567   20031114
        WO 2004050681   A3   20041104
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
            TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG
        CA 2506546   A1   20040617   CA 2003-2506546   20031114
        AU 2003302665   A1   20040623   AU 2003-302665   20031114
        EP 1581309   A2   20051005   EP 2003-812437   20031114
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
        JP 2006510727   T   20060330   JP 2004-570758   20031114
        US 2006122171   A1   20060608   US 2005-533555   20050502
PRIORITY APPLN. INFO.:   US 2002-426680P   P 20021115

                                              US 2003-470674P   P 20030514

                                              WO 2003-US36567   W 20031114

OTHER SOURCE(S):   MARPAT 141:54195
GI

AB   The title compds. I [W = N or CR1; R1 = H, halo, trihaloalkyl, CN, NH2,
      NO2, OR6, N=CNR6R7, N(R6)C(=NR8)NR6R7, SR6, S(O)1-2R6, SO2NR6R7, CO2R6,
      etc.; L = O, S(O)0-2, or NR3; Q = C or N, when Q = N, then R4 does not
      exist; R2, R3 = H or R7; R4, R5 = H, OR6, NR6R7, S(O)0-2R6, SO2NR6R7,
      CO2R6, C(O)NR6R7, N(R6)SO2R6, NC(O)2R6, C(O)R7, CN, NO2, NH2, halo,
      trihaloalkyl, R7; or R4, R5 when taken together, form a five or
      six-membered aromatic ring containing 0-2 N; R6, R7 = H,
      (substituted)(aryl)alkyl, (substituted)heterocyclylalkyl,
      (substituted)aryl, (substituted)heterocyclyl, with proviso or R6, R7 =
      when taken together with a common N to which they are attached, form a
      five to seven-membered heterocyclic ring containing at least one addnl.
      heteroatom selected from N, O, S, or P; R8 = H, NO2, CN, OR6, or
      (substituted)alkyl; X = (substituted)(hetero)aromatic ring; K = O, S,
      (substituted)amino] were prepared as kinase modulators to treat
      kinase-dependent diseases and conditions. For example compound II was
      prepared in a multi-step synthesis starting from 4-methylimidazole. The
      latter inhibited KDR and EGFR with IC50 < 50 nM.
IT   705945-80-8P 705945-81-9P 705945-82-0P
      705945-83-1P 705945-84-2P 705945-85-3P
      705945-86-4P 705945-87-5P 705945-88-6P
      705945-89-7P 705945-90-0P 705945-92-2P
      705945-93-3P 705945-94-4P 705945-95-5P
      705945-96-6P 705945-97-7P 705945-98-8P
      705945-99-9P 705946-00-5P 705946-01-6P
      705946-02-7P 705946-03-8P 705946-04-9P
      705946-05-0P 705946-06-1P 705946-07-2P
      705946-14-1P 705946-15-2P 705946-16-3P
      705946-17-4P 705946-18-5P 705946-19-6P
      705946-21-0P 705946-22-1P 705946-23-2P
      705946-24-3P 705946-25-4P 705946-26-5P

```
705946-27-6P 705946-28-7P 705946-29-8P
705946-30-1P 705946-31-2P 705946-32-3P
705946-33-4P 705946-34-5P 705946-35-6P
705946-36-7P 705946-37-8P 705946-38-9P
705946-39-0P 705946-40-3P 705946-41-4P
705946-42-5P 705946-43-6P 705946-44-7P
705946-45-8P 705946-46-9P 705946-47-0P
705946-48-1P 705946-49-2P 705946-50-5P
705946-51-6P 705946-52-7P 705946-53-8P
705946-54-9P 705946-55-0P 705946-56-1P
705946-57-2P 705946-58-3P 705946-59-4P
705946-60-7P 705946-61-8P 705946-62-9P
705946-64-1P 705946-65-2P 705946-66-3P
705946-67-4P 705946-68-5P 705946-69-6P
705946-70-9P 705946-71-0P 705946-72-1P
705946-73-2P 705946-74-3P 705946-76-5P
705946-77-6P 705946-78-7P 705946-79-8P
705946-80-1P 705946-81-2P 705946-82-3P
705946-83-4P 705946-84-5P 705946-85-6P
705946-86-7P 705946-87-8P 705946-88-9P
705946-89-0P 705946-90-3P 705946-91-4P
705946-92-5P 705946-93-6P 705946-94-7P
706816-70-8P
```

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
       (prepn. of oxindole derivs. as kinase modulators)
RN   705945-80-8 CAPLUS
CN   2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-
1H-benzimidazol-2-yl)phenylmethylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-81-9 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-(1H-
imidazol-2-ylphenylmethylene)-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-82-0 CAPLUS
CN   2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-
1H-benzimidazol-2-yl)(4-methoxyphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-83-1 CAPLUS
CN   2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-
1H-benzimidazol-2-yl)(4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-84-2 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylene]-5-[(1-
ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-85-3 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-methoxyphenyl)methylene]-5-[(1-
ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN   705945-86-4 CAPLUS
CN   2H-Indol-2-one, 3-(1H-benzimidazol-2-ylphenylmethylene)-5-[(1-ethyl-4-
piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-87-5 CAPLUS
CN   2H-Indol-2-one, 1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-
yl)phenylmethylene]-5-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-, (3Z)-
(CA INDEX NAME)

Double bond geometry as shown.

RN   705945-88-6 CAPLUS
CN   2H-Indol-2-one, 3-[(4-aminophenyl)-1H-benzimidazol-2-ylmethylene]-5-[(1-
ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-89-7 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-methylphenyl)methylene]-5-[(1-
ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-90-0 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-
imidazol-2-yl(4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-92-2 CAPLUS

CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-
      imidazol-2-yl(4-methoxyphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-93-3 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-94-4 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylene]-5-
      [(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-95-5 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-96-6 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-97-7 CAPLUS
CN   Benzonitrile,
      3-[(Z)-1H-benzimidazol-2-yl[5-[(1-ethyl-4-piperidinyl)amino]-
      1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-98-8 CAPLUS
CN   2H-Indol-2-one, 3-[(3-aminophenyl)-1H-benzimidazol-2-ylmethylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705945-99-9 CAPLUS
CN   2H-Indol-2-one, 3-(1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-5-(4-
      piperidinylamino)-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-00-5 CAPLUS
CN   Benzenecarboximidamide, 3-[(Z)-1H-benzimidazol-2-yl[5-[(1-ethyl-4-
      piperidinyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (CA
      INDEX NAME)

Double bond geometry as shown.

RN   705946-01-6 CAPLUS
CN   2H-Indol-2-one,
      3-(1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-5-[[1-
      (2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-02-7 CAPLUS
CN   2H-Indol-2-one, 3-(1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-5-
      [(2,2,6,6-tetramethyl-4-piperidinyl)amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-03-8 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-methoxyphenyl)methylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-04-9 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-05-0 CAPLUS
CN   1H-Isoindole-1,3(2H)-dione,
2-[2-[2-[(Z)-[5-[(1-ethyl-4-piperidinyl)amino]-

1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]-1H-imidazol-5-yl]ethyl]-
      (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-06-1 CAPLUS
CN   2H-Indol-2-one, 3-(1H-benzimidazol-2-ylphenylmethylene)-5-[[1-[2-
      (dimethylamino)ethyl]-4-piperidinyl]amino]-1,3-dihydro-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-07-2 CAPLUS
CN   2H-Indol-2-one,
3-(1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-5-[[1-

Double bond geometry as shown.

RN   705946-17-4 CAPLUS
CN   2H-Indol-2-one,
3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-18-5 CAPLUS
CN   2H-Indol-2-one,
3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylene]-1,3-
      dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

Double bond geometry as shown.

RN   705946-14-1 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylene]-1,3-
      dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-15-2 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-methoxyphenyl)methylene]-1,3-
      dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-16-3 CAPLUS
CN   2H-Indol-2-one,
3-[(3-chlorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

RN   705946-19-6 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylene]-5-[(1-
      ethyl-4-piperidinyl)methylamino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-21-0 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-22-1 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylene]-1,3-
      dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-23-2 CAPLUS
CN   2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylene]-1,3-
      dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-24-3 CAPLUS
CN   2H-Indol-2-one,
3-[(3-chlorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-
4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-25-4 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)-1H-
imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-26-5 CAPLUS

RN   705946-29-8 CAPLUS
CN   2H-Indol-2-one,
3-[(3-chloro-4-fluorophenyl)-1H-imidazol-2-ylmethylene]-5-
[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-30-1 CAPLUS
CN   2H-Indol-2-one, 3-[(3,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-
ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

CN   2H-Indol-2-one,
3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylene]-
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-27-6 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)(5-
methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-28-7 CAPLUS
CN   2H-Indol-2-one,
3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylene]-
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-31-2 CAPLUS
CN   2H-Indol-2-one, 3-[(6-chloro-1H-benzimidazol-2-yl)phenylmethylene]-5-[(1-
ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-32-3 CAPLUS
CN   2H-Indol-2-one, 3-[(6-chloro-1H-benzimidazol-2-yl)(3,5-
difluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-,
(3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-33-4 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-
methylphenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX
NAME)

Double bond geometry as shown.

RN   705946-34-5 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(4-fluorophenyl)-1H-
      imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-35-6 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-
      imidazol-2-yl(4-propylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-36-7 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-
      imidazol-2-yl[4-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-37-8 CAPLUS
CN   2H-Indol-2-one, 3-[(3,5-difluorophenyl)(6-fluoro-1H-benzimidazol-2-
      yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA
      INDEX NAME)

Double bond geometry as described by E or Z.

RN   705946-38-9 CAPLUS
CN   2H-Indol-2-one, 3-[(3,5-difluorophenyl)(6-fluoro-1H-benzimidazol-2-
      yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
      INDEX NAME)

Double bond geometry as shown.

RN   705946-39-0 CAPLUS
CN   2H-Indol-2-one, 3-[(3-fluoro-4-methylphenyl)-1H-imidazol-2-ylmethylene]-
      1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA
INDEX
      NAME)

Double bond geometry as shown.

RN   705946-40-3 CAPLUS
CN   2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-
      1H-imidazol-2-yl)(4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-41-4 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[[3-fluoro-4-
      (trifluoromethyl)phenyl]-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)-
      (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-42-5 CAPLUS
CN   2H-Indol-2-one,
3-[(4-chlorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-
      4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-43-6 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-
      methylphenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)-
      (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-44-7 CAPLUS
CN   2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-
      1H-imidazol-2-yl)[6-(trifluoromethyl)-3-pyridinyl]methylene]-, (3Z)- (CA
      INDEX NAME)

Double bond geometry as shown.

RN   705946-45-8 CAPLUS
CN   2H-Indol-2-one,
1,3-dihydro-3-[1H-imidazol-2-yl(4-methylphenyl)methylene]-
      5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-46-9 CAPLUS
CN   2H-Indol-2-one, 3-[(3-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-
      1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA
INDEX
      NAME)

Double bond geometry as shown.

RN   705946-47-0 CAPLUS
CN   2H-Indol-2-one, 1,3-dihydro-3-[1H-imidazol-2-yl[4-
      (trifluoromethyl)phenyl]methylene]-5-[[1-(2-methoxyethyl)-4-
      piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-48-1 CAPLUS
CN   2H-Indol-2-one, 3-[(6-chloro-1H-benzimidazol-2-yl)phenylmethylene]-1,3-
      dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-49-2 CAPLUS
CN   2H-Indol-2-one, 3-[(3,5-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-50-5 CAPLUS
CN   2H-Indol-2-one, 3-[(3,5-difluorophenyl)(5-methyl-1H-imidazol-2-
      yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
      INDEX NAME)

Double bond geometry as shown.

RN   705946-51-6 CAPLUS
CN   2H-Indol-2-one, 3-[(3,5-difluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-
      dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-52-7 CAPLUS
CN   2H-Indol-2-one, 3-[(3,5-difluorophenyl)(5-methyl-1H-imidazol-2-
      yl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-,
      (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-53-8 CAPLUS
CN   2H-Indol-2-one,
      1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-3-
   [(5-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylene]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-54-9 CAPLUS
CN   2H-Indol-2-one,
      3-[(4-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-55-0 CAPLUS
CN   2H-Indol-2-one, 3-[(3,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-
      dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-56-1 CAPLUS
CN   2H-Indol-2-one, 3-[(3-chloro-4-fluorophenyl)-1H-imidazol-2-ylmethylene]-
      1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA
INDEX
      NAME)

Double bond geometry as shown.

RN   705946-57-2 CAPLUS
CN   2H-Indol-2-one,
      3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-(4-piperidinylamino)-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-58-3 CAPLUS
CN   2H-Indol-2-one,
      3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-[[1-[2-(1-piperidinyl)ethyl]-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-59-4 CAPLUS
CN   2H-Indol-2-one,
      3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-[[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]amino]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-60-7 CAPLUS
CN   2H-Indol-2-one, 5-[[1-[2-(diethylamino)ethyl]-4-piperidinyl]amino]-3-[(3-
      fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX
   NAME)

Double bond geometry as shown.

RN   705946-61-8 CAPLUS
CN   2H-Indol-2-one,
3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-[[1-[2-(1-pyrrolidinyl)ethyl]-4-piperidinyl]amino]-, (3Z)-   (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-62-9 CAPLUS
CN   2H-Indol-2-one,
1,3-dihydro-3-[1H-imidazol-2-yl(4-methylphenyl)methylene]-
      5-[(1-methyl-4-piperidinyl)amino]-, (3Z)-   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-64-1 CAPLUS
CN   1H-Imidazole-5-carboxylic acid,
2-[(Z)-[1,2-dihydro-5-[[1-(2-methoxyethyl)-
      4-piperidinyl]amino]-2-oxo-3H-indol-3-ylidene](3-fluorophenyl)methyl]-4-
      methyl-, ethyl ester   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-65-2 CAPLUS
CN   2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-2-ylphenylmethylene)-5-[[1-(2-
      methoxyethyl)-4-piperidinyl]amino]-, (3Z)-   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-66-3 CAPLUS
CN   2H-Indol-2-one,
1,3-dihydro-3-[1H-imidazol-2-yl(4-methoxyphenyl)methylene]-
      5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)-   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-67-4 CAPLUS
CN   2H-Indol-2-one,
3-[(4-chlorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)-   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-68-5 CAPLUS
CN   2H-Indol-2-one, 3-[[3-fluoro-4-(trifluoromethyl)phenyl]-1H-imidazol-2-
      ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-,
   (3Z)-   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-69-6 CAPLUS
CN   2H-Indol-2-one,
3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
      5-[[1-(methylsulfonyl)-4-piperidinyl]amino]-, (3Z)-   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-70-9 CAPLUS
CN   2H-Indol-2-one,
1,3-dihydro-3-[1H-imidazol-2-yl(4-propylphenyl)methylene]-
      5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)-   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-71-0 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)(5-
   phenyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-72-1 CAPLUS
CN   2H-Indol-2-one, 3-[(3-fluorophenyl)(5-phenyl-1H-imidazol-2-yl)methylene]-
      1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA
INDEX
      NAME)

Double bond geometry as shown.

RN   705946-73-2 CAPLUS
CN   2H-Indol-2-one, 3-[(3-fluoro-4-methylphenyl)(5-methyl-1H-imidazol-2-
      yl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-,
      (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-74-3 CAPLUS
CN   2H-Indol-2-one, 1,3-dihydro-3-[1H-imidazol-2-yl[6-(trifluoromethyl)-3-
      pyridinyl]methylene]-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)-
      (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-76-5 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[[2-fluoro-4-
      (trifluoromethyl)phenyl]-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)-
   (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-77-6 CAPLUS
CN   2H-Indol-2-one,
      5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-
      1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX
   NAME)

Double bond geometry as shown.

RN   705946-78-7 CAPLUS
CN   2H-Indol-2-one,
3-[(4-chlorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-
      [(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-79-8 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[[3-fluoro-4-

(trifluoromethyl)phenyl](5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-
      , (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-80-1 CAPLUS
CN   2H-Indol-2-one, 3-[(3,4-difluorophenyl)(5-methyl-1H-imidazol-2-
      yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
   INDEX NAME)

Double bond geometry as shown.

RN   705946-81-2 CAPLUS
CN   2H-Indol-2-one, 3-[(3-chloro-4-fluorophenyl)(5-methyl-1H-imidazol-2-
   yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
   INDEX NAME)

Double bond geometry as shown.

RN   705946-82-3 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(4-fluorophenyl)(5-
   methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-83-4 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluorophenyl)-1H-
      imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-84-5 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[[2-fluoro-4-

(trifluoromethyl)phenyl](5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-
      , (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-85-6 CAPLUS
CN   2H-Indol-2-one, 3-[(2,3-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-
   ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-86-7 CAPLUS
CN   2H-Indol-2-one, 3-[(2,3-difluorophenyl)(5-methyl-1H-imidazol-2-
      yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
   INDEX NAME)

Double bond geometry as shown.

RN   705946-87-8 CAPLUS
CN   2H-Indol-2-one, 3-[(2,4-difluorophenyl)(5-methyl-1H-imidazol-2-
      yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
   INDEX NAME)

Double bond geometry as shown.

RN   705946-88-9 CAPLUS
CN   2H-Indol-2-one, 3-[(2,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-
      ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-89-0 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluorophenyl)(5-
      methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

RN   705946-90-3 CAPLUS
CN   2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-
   imidazol-2-yl[3-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX
      NAME)

Double bond geometry as shown.

RN   705946-91-4 CAPLUS
CN   2H-Indol-2-one,
      5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-
      1H-imidazol-2-yl)[3-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX
   NAME)

Double bond geometry as shown.

RN   705946-92-5 CAPLUS
CN   2H-Indol-2-one, 3-[(2,4-dichloro-5-fluorophenyl)-1H-imidazol-2-
      ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
   INDEX NAME)

Double bond geometry as shown.

RN   705946-93-6 CAPLUS
CN   2H-Indol-2-one, 3-[(2,4-dichloro-5-fluorophenyl)(5-methyl-1H-imidazol-2-
      yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
   INDEX NAME)

Double bond geometry as shown.

RN   705946-94-7 CAPLUS
CN   2H-Indol-2-one, 3-[(4-chloro-2-fluorophenyl)(5-methyl-1H-imidazol-2-
      yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
   INDEX NAME)

Double bond geometry as shown.

RN   706816-70-8 CAPLUS
CN   2H-Indol-2-one,
      5-(8-azabicyclo[3.2.1]oct-3-ylamino)-3-(1H-benzimidazol-2-
      ylphenylmethylene)-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

=>